University of Central Florida

STARS
Retrospective Theses and Dissertations
1987

Analysis of Immune Enhancing Effects of Interleukin-2
Sharareh Sazesh
University of Central Florida

Part of the Microbiology Commons

Find similar works at: https://stars.library.ucf.edu/rtd
University of Central Florida Libraries http://library.ucf.edu
This Masters Thesis (Open Access) is brought to you for free and open access by STARS. It has been accepted for
inclusion in Retrospective Theses and Dissertations by an authorized administrator of STARS. For more information,
please contact STARS@ucf.edu.

STARS Citation
Sazesh, Sharareh, "Analysis of Immune Enhancing Effects of Interleukin-2" (1987). Retrospective Theses
and Dissertations. 5042.
https://stars.library.ucf.edu/rtd/5042

ANALYSIS OF IMMUNE ENHANCING
EFFECTS OF INTERLEUKIN-2

BY
SHARAREH SAZESH

B.S., University of Florida, 1983

THESIS

Submitted in partial fulfillment of the requirements for
the Master of Science degree in Microbiology in the
Graduate Studies Program of the College of Arts and Sciences
University of Central Florida
Orlando, Florida

Summer Term
1987

ABSTRACT

The effectiveness of IL-2 in the enhancement of immune
responses in B6-AKR and normal B6 mice was investigated.

In

vivo treatment of chimeras with murine IL-2 partially
restored PFC respons e s of their splenocytes to SRBC.

This

treatment suppressed splenocyte IL-2 production in chimeras.
In vivo treatment of chimeras with rhIL-2 resu l ted in a
slight enhancement of mitogenic responses to Con-A.

This

treatment had no significant effect on mitogenic responses
to PHA.

The rhIL-2 treatment did not result in suppression

of IL-2 production by chimeric ~plenocytes.
Recombinant human IL-2 enhanced mitogenic responses of
normal B6 and chimeric mice to PHA in all age groups tested.
However, the mitogenic response to Con-A was enhanced only
in older mice (130 days post-transplant).
The duration of rhIL-2 exposure time was critical for
the enhancement of mitogenic responses of B6 splenocytes to
PHA.

The enhancement of thymocyte mitogeneic responses to

Con-A or PHA was also dependent on the length of incubation
time with rhIL-2.

However, the enhancement of Con-A

mitogenesis was independent _of the duration of exposure time
to rhIL-2.
Treatment of mitogen-stimulated splenocytes with 7D4
antibody greatly inhibited cell proliferation of several
concentrations of mitogen tested.

The 7D4 antibody

significantly inhibited the response of thymocytes cultured
with rhIL-2 to PHA or Con-A.

Studies with 7D4 antibody

provided direct evidence for the involvement of IL-2 in the
proliferation of splenocytes to T-cell mitogens and the
proliferation of thymocytes in co-stimulatory assays.
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INTRODUCTION

Bone Marrow Transplantation
There has been an increasing growth in the use of bone
marrow transplantation (BMT) for the

treatment of immuno-

deficiency, severe aplastic anemia and leukemia (1).

This

has been the result of technological advancements in marrow
preparation leading to successful BMT in humans (1), and
experimental animals (2-7).

Allogeneic BMT in humans has

been limited to major histocompatibility complex (MHC) matched (HLA), and non-mixed lymphocyte culture (MLC)reactive donor-recipient combinations.

This limitation is

due to the high risk of severe graft-versus-host disease
(GVHD) when histoincompatible combinations are used.
Approximately 35 to 40% of prospective marrow transplanted
patients have an HLA-identical sibling who can serve as a
marrow donor (1).

An important objective in BMT research is

to make this form of treatment available to patients who
lack HLA-matched donors.
There are two major problems associated with transplantation of allogeneic bone marrow.

These problems are

directly related to the presence of two sets of immune
cells.

The first consisting of the recipient's immune

system ( fu_n ctional T-cells), .attempts to reject the
transplanted bone marrow.

This results in a
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host-versus-graft response (HVGR).

The second problem

occurs with immunocompetent cells present in the marrow
graft (mature T-cells) which react against the recipient,
resulting in GVHD (8).
Studies of allogeneic BMT have shown that T-cells which
contaminate bone marrow grafts play a major role in the
induction of GVHD (2-5).

The depletion of T-cells from such

grafts in vitro with monoclonal anti-T-cell antibody and
complement completely protected animals from lethal GVHD (4,
5, 8, 9).

Lethally irradiated mice which were infused with

allogeneic bone marrow treated with anti-Thy 1 with or
without complement, survived for 100 to 170 days posttransplant • . This treatment also resulted in complete
chimerism and immunocompetence of these chimeras (2, 3, 4).
Krown et al.

(9) reported the construction of H-2

al!ogeneic chimeras using C57BL/6J (B6)

(H-2 b ) donors and

irradiated CBA/J (H-2k) mice as recipients.

No evidence of

GVHD was apparent in these chimeras when marrow was treated
with anti-Thy 1.2 and complement prior to infusion.
Experimental models using AKR mice (H-2k) have also
been developed for evaluating allogeneic BMT procedures
(2,3,7,10).

The AKR strain of mice develop spontaneous

leukemia between 6 to 12 months of age (2,3,7).
al.

Tanaka et

(7) reported that AKR mice could be protected from the

development of spontaneous leuk~mia by infusion of
allogeneic marrow which was matched at the H-2 locus of the

3

recipient.

The infusion of CBA/H ( H-2k·) marrow rendered AKR

mice leukemia resistant.

These stable CBA/H-AKR chimeras

continued to live for 14 to 18 months without evidence of
leukemia.

"-

The development of spontaneous leukemia in AKR mice has
also been prevented by infusion of allogeneic marrow from
donors not matched at the H-2 locus.

Onoe et al.

(2 )

r~ported the preparation of long-lived allogeneic chimeras
in which donors and recipients differed at the MHC barrier.
Allogeneic chimeras [B6-AKR] showed no evidence of GVHD when
anti-Thy 1.2 antise~um-treated _marrow cells were infused
into lethally irradiated AKR recipients.

Thymus and spleen

cells of these chimeras were shown to be predominantly of
donor type.

Immune functions in these chimeras were

analyzed approximately 100 days posttransplant (2).

These studies reported normal proliferative

responses of chimeric splenocytes to concanavalin A (Con-A),
phytohemagglutinin (PHA) and lipopolysaccharide (LPS).
Natural killer (NK) cell and antibody-dependent cell

.

mediated cytotoxic activity were also within a normal range.
However, primary antibody responsiveness to sheep red blood
cells (SRBC) failed to develop in these chimeras.

Longley

and Good (3) performea further analysis of long-term
survival and immune functions of fully allogeneic B6-AKR and
allogeneic CBA-AKR chimeras.

The infusion of lethally ·

irradiated AKR (H-2k) recipients with MHC-matched marrow
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from CBA/J (H-2k) mice or MHC-mismatched marrow from B6
(H-2b) mice, protected AKR mice from the development of
spontaneous leukemia.

Ninety-eight percent of H-2

compatible allogeneic chimeras [CBA-AKR] were still alive
280 days post-transplant.

However, B6-AKR chimeras began

dying 170 days post-transplant due to a wasting syndrome of
undetermined etiology (3).

In contrast to normal responses

observed in CBA-AKR chimeras, B6-AKR chimeras (170 to 280
days post-transplant) showed suppressed Con-A mitogenesis
and deficient interleukin-2 (IL-2) production.

Primary

antibody responses to both in vitro and in vivo stimulation
with SRBC were also deficient in these chimeras.

The

addition of purifi~d rat IL-2 to splenocyte cultures of
long-lived (170 to 280 days post-transplant) chimeras
restored the deficient in vitro antibody responses to SRBC.
It was further demonstrated that in vivo administration of
murine IL-2, 48 hr prior to analysis, restored in vitro
antibody responses.

Normal antibody response to a secondary

challenge with SRBC in vivo has been previously reported
(2,3), in similar chimeric combinations.

These findings

suggest the presence of necessary cellular elements required
for T-dependent antibody responses of chimeric splenocytes.
Onoe et al.

(11) reported the existence of a minor

subpopulation of helper T-cells in similar chimeras.

This

subpopulation could expand and interact with antigen
presenting cells of donor type (H-2I incompatible) upon
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repeated or continued stimulation with SRBC.

Matching of

T-cells and antigen presenting cells was required for the
primary antibody response to SRBC.

Onoe et al.

(12)

reported that T-cells from chimeras cooperated with
non-T-cells bearing recipient type MHC antigens.

The

addition of adherent cells of recipient MHC type in which
matches involved IE and IA compatibility corrected the
deficient primary antibody response to SRBC (11,12).
Activation of T-cells by Mitogens
A number of substances, primarily plant lectins, have
been shown to activate T-cells _ ( 13-17) •

The term "lectin

refers to a large group of multimeric glycoproteins.
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These

glycoproteins bind and cross-link specific carbohydrate
determinants displayed on the surface of lymphocytes (17).
Some lectins trigger a large proportion of lymphocytes to
divide and synthesize DNA (13-17).
are referred to as mitogens.
routinely used to study
lymphocyte activation.

These type of lectins

Mitogenic lectins are

early biochemical events involving
Mitogen stimulation of lymphocytes

in vitro is believed to mimic a series of events which
occurs in vitro following the stimulation with specific
antigens (13-19).

Mitogens are selective in their

stimulatory effects on Band T lymphocytes (15-19).

Two of

the most commonly used mitogens, PHA and Con-A, specifically
activate T-cells in both human (_18), and mouse lymphoid · cell
populations (15-19).

Other mitogens, such as LPS and

6

pokeweed mitogen (PWM) specifically activate B-cells (14,
15).
Both Con-A and PHA stimulate DNA synthesis and blast
transformation of splenic lymphocytes (13-17).

In general,

Con-A stimulation results in greater proliferative responses
of T-cells at various cell densities, mitogen concentrations
and culture durations compared to PHA (17).

The stimulation

of T-cells occurs at a certain concentration range of these
mitogens

(15-17).

Differential capacities of various

lymphoid populations in response to PHA and Con-A were
described by Stobo et al.

They demonstrated that

(17).

Con-A activates DNA synthesis in thymocytes, cortisonetreated thymocytes and spleen cells.

In contrast, PHA

stimulation results in minimal proliferation of thymocytes.
Despite the heterogeneity of mouse lymphoid cell populations
in their responses to mitogens, similar amounts of
radiolabeled mitogen ([ 125 I] PHA,

[ 125 I] Con-A) binds to the

surface of all lymphoid cells (17).

The quantity of mitogen

bound is dependent on the temperature, concentration and
duration of the mitogen pulse.

The binding of mitogen to

its cell surface receptor is rapid, being complete in
·
1 y 30 mi·nutes at 37°C.
approximate

However, a prolonged

contact between mitogen and T-cells is required for optimal
stimulation (16-17).

The induction of DNA synthesis in

lymphocytes requires at least a 20 hr exposure to the
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mitogen.

More than 48 hr contact with the mitogen is

required for optimal thymidine incorporation on day 3 and 4
(16).

These observations suggest that binding is necessary

but not a sufficient cause for activation.

Since thymus

cells bind to both PHA and Con-A, but only Con-A results in
thymocyte stimulation, i t has been suggested that binding of
the mitogen to the cell surface is not the only requirement
for cell activation (17).

Cell activation events lead to

cellular proliferation which is dependent on the continued
presence of other factors liberated by the cells themselves.
These factors, known collectively as "lymphokines", regulate
cell proliferation and subsequent growth of a number of cell
types

(20-23).
IL-2

Since i t was discovered that IL-2 regulates T-cell
growth,

i t has been a focus of scientific research (20-27).

Interleukin-2, formerly known as T-cell growth factor
(TCGF),

is a glycoprotein synthesized and secreted by

activated T-cells.

Interleukin-2 functions as a

hormone-like growth factor for many subsets of T-cells (20).
Interleukin-2 dependent murine cell lines such as, HT-2
and CTLL-2

(22), have been established.

(21)

These cell lines

have made possible the development of a standard quantitative microassay for the detection of IL-2 in cell culture
supernatants (26).

This development,in turn, has aided

the
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study of biochemical and functional characteristics of this
lymphokine.
In the murine system, IL-2 (TCGF} was originally
described as an activity which was present in the
supernatants of Con-A stimulated spleen cells.

These

supernatants supported the proliferation of both cytotoxic
and helper T-cells in culture (23,26}.

Maximum IL-2

activity was detected 12 to 48 hr after Con-A stimulation
(23,27}.

The production of IL-2 is T-cell specific.

Mature Thy

l+ cells are required for this _production and only T-Fell
lectins can elicit IL-2 release (20,23,27}.

However, both

T-cells and adherent cells (macrophages} participate in the
production of IL-2.

Activated macrophages produce

interleukin-I (IL-1) which in turn stimulates T-cells to
release IL-2 (20,27,28).
Interleukin-2 induces the clonal expansion of T-cells
for the generation of T-cell immune responses (20-27}.
Smith et al.

(29} reported that T-cells activated by lectin

or antigen could absorb IL-2 activity in a time and cell
concentration dependent manner.

These cells continued to

proliferate following this absorption process.
al.

Gillis et

(26} observed that T-cell lectins, alone, could not

support the continuous proliferation of T-cells.

However,

,I

conditioned medium containing both lectin and IL-2,
initiated and sustained T-cell growth.

These observations
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have suggested that IL-2 itself functions as a T-cell
mitogenic signal rather than lectin or antigen (26,30,31).
Experiments utilizing monoclonal antibody directed against
the IL-2 molecule have provided further evidence that IL-2
production is obligatory for T-cell mitogenesis.
al.

Gillis et

(32) reported that the addition of monoclonal anti-IL-2

IgG to cultures of Con-A stimulated murine splenocytes
inhibited mitogen-induced proliferation.

However, an

initial signal supplied by the binding of mitogen to the
cell membrane has been shown to be a requirement for the
activation of T-cells.

This activation leads to an IL-2

responsive state (20,23,27).

Although, mature T-cells

produce IL-2 (20,23), both mature and immature T-cells
respond to IL-2.

Smith et al.

(27) reported that thymocytes

(immature T-cells), and mature splenocytes responded to the
proliferative stimulus of IL-2.

These findings suggested

that IL-2 responsive and IL-2 producing cells might belong
to distinct subsets.

Wagner and Rollinghoff (33) reported
. response
that cytotoxic T-cells (Lyl - 2 + 3 + ) proliferated in
to IL-2, while helper T-cells (Lyl + 2 - 3 - )were involved in
IL-2 production.
Murine and human IL-2 have been purified by gel
filtration,

ion exchange chromatography, and isoelectric

focusing (24,23).

Analysis of the biochemical and

biological properties of IL-2 has revealed species
differences in ·its function and molecular weight (MW)
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(20,24).

Murine IL-2 has a MW of 30,000 while human IL-2

has a MW of 15,000 (24).

Species differences in biological

activity of IL-2 were first reported when the mitogenic
effects of IL-2 from humans, rats, and mice were compared
(20,24).

Human and rat IL-2 promoted the proliferation of

murine T-cells, while murine and rat IL-2 had no detectable
activity on human T-cells.
Human IL-2 supports the growth of T-cell populations
activated in vitro (34).

Human IL-2 enhances thymocyte

mitogenesis (35), and induces T-helper cells for antibody
forming responses (36).

It also regulates the activity of

cytotoxic T-cells (37) NK cells (38), and lymphokine
activated killer (LAK) cells (39).
Human IL-2 is produced in minute quantities by
peripheral blood lymphocytes upon stimulation with T-cell
lectins (40).

The need for large amounts of purified IL-2

prompted the isolation and cloning of the human IL-2 gene.
The availability of recombinant human IL-2 (rhIL-2) has
greatly facilitated its biological and clinical study
(40-42).

The imrnunomodulatory properties of rhIL-2 have

been tested in a variety of in vitro and in vivo murine
immunological assays (40-42).

These studies have revealed

that native IL-2 and rhIL-2 function equivalently.
Recombinant human IL-2 provides significant helper activity
for the stimulation of both human and mouse lymphocyte
proliferation (40-42).
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IL-2 Receptor
The current model of lectin-stimulated T-cell
activation proposes that interaction of the lectin with
T-cells induces expression of IL-2 specific receptors
(30,31,43,44).

Concanavalin A stimulates polyclonal

proliferation of T-cells by inducing the production of IL-2,
and its membrane receptors (43,45,46).

A model of

ligand-activated IL-2-induced proliferation of T-ce l ls has
been developed (43).

According to this model, ligand

(antigen or mitogen) induces the production of IL-2 by
helper T-cells, and the expres~ion of the IL-2 receptor on
responder T-cells.

The responder cells, in turn,

proliferate upon the binding of IL-2 to its receptor.
Interleukin-2 receptor expression on responder cells
requires a specific interaction of ligand with selective
sites on the cell membrane.
The demonstration of an IL-2 specific binding site has
been made possible with the development of a radiolabeled
IL-2 binding assay (45).

The binding of [ 35 s] methionine-

IL-2 to CTLL-2 cells proceeds rapidly at 37°c and reaches a
maxium level within 15 minutes.

The binding is specific,

saturable, and occurs with high affinity.

There is a close

correlation between the concentration of IL-2, the
proliferative response, and the occupation of the IL-2
receptor site (45).

Interleukin-2 receptors are detectable

4 hr after mitogen stimulation.

Maximum levels of IL-2
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receptors occur between 24 to 48 hr after culture initiation
(46).

Two classes of IL-2 receptor binding sites have been

identified according to their affinity for IL-2 (47).

The

lower affinity site accounts for 85 to 95% of IL-2 receptors
expressed on the surface of activated T-cells.

The

remaining receptors (10%) exhibit a higher affinity binding
site.

The proliferative response of T-cells to mitogenic

stimuli is believed to be the result of the interaction of
IL-2 with the high affinity form of its receptor (47,48).
Monoclonal antibodies that detect IL-2 receptors have
been recently reported by seve~al laboratories (49-51).

The

7D4 rat IgM monoclonal antibody described by Malek et al.
(49) recognizes epitopes distinct from the IL-2 binding site
on murine T-cells.

This antibody has been shown to inhibit

IL-2 dependent cell proliferation of HT-2 and CTLL-2 cells,
without inhibiting IL-2 binding (49).

The level of

inhibition of proliferation is dependent on both antibody
and IL-2 concentration.

Maximal inhibition occurs at low

IL-2 and high antibody concentrations (49).

It has been

suggested that 7D4 may selectively reduce the affinity of
high affinity IL-2 receptors.

This reduction of receptor

affinity could result in suppression of IL-2 dependent cell
proliferation without inhibition of IL-2 binding (49).
It is difficult to detect a significant IL-2 receptor
bearing T-cell population in ~nstimulated spleen cell
cultures (45,49).

However, non-specific stimulation with
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mitogen in vitro results in a significant increase in the
expression of high affinity IL-2 receptors.

Concanavalin A

stimulated cells bear significantly higher numbers of IL-2
receptors than PHA stimulated cells (46).

The level of IL-2

receptor expression is dependent on the mitogen
concentration (46).
The physiologically limiting variables which determine
the magnitude of T-cell proliferative responses are IL-2
concentration, receptor expression and receptor affinity
(20,30,45,49).
The objective of the present study was to analyze the
effectiveness of IL-2 in the eQhancement of immune responses
in AKR mice made leukemia resistant by infusion with
allogeneic bone marrow.

The effect of in vivo treatment of

B6-AKR chimeras with crude preparations of murine IL-2 on
primary antibody response to in vivo sensitization with SRBC
was measured.

The in vivo effect of rhIL-2 on mitogenic

responses of chimeric splenocytes to PHA and Con-A was also
analyzed.

The immunological state of B6-AKR chimeras at

various days following transplant was compared to
age-matched normal B6 controls.

The proliferative responses

of their splenocytes to Con-A, PHA and rhIL-2 were compared.
Kinetic studies were performed on the enhancing effect of
rhIL-2 on proliferative responses of B6 splenocytes and
thymocytes to PHA and Con-A.

The contribution of IL-2 in

the proliferative response of splenocytes and thymocytes to
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PHA or Con-A was tested by using anti-IL-2 receptor
monoclonal antibody 7D4.

MATERIALS AND METHODS
Animals
AKR/J and B6 male and female mice were used in this
study (Jackson Laboratory, Bar Harbor, ME).
Culture Medium
All assays were performed in complete medium consisting
of RPMI 1640 (KC Biological, Lenexa, KS) supplemented with
10% heat inactivated fetal bovine serum (Sigma Biological
Co.,

St. Louis, MO), 100 units (U) per ml penicillin, 100

ug/ml streptomycin,

5.0 x 10 -5 M mercaptoethanol, and 2 mM

1-glutamine (KC Biological).
Preparation of Bone Marrow Cells
Marrow cells were prepared under sterile conditions in
a manner similar to that described by Once et al.
Donor marrow was obtained from B6 mice.
sacrificed by cervical dislocation.

(2).

Donors were

Bone marrow cells were

obtained from tibia and femur by gentle aspiration with
complete medium using a 25 gauge needle and syringe.

The

resulting cell suspension was placed on ice for 5 minutes to
allow the cellular debris to settle to the bottom of the
tube.
400

X

The supernatant was removed, and centrifuged at
g.

The cell pellet was gently resuspended in complete

medium and viable (trypan blue exclusion) cell counts were
.

determined.

Marrow suspensions were adjusted to 1.0 x 10
15

8
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cells/ml and were mixed with an equal volume of a 1:10
dilution of anti-Thy 1.2 alloantiserum (Accurate Chemical
and Scientific Corp. Westbury, NY).

Cells were incubated on

ice for 30 minutes with occasional mixing.

The cell

suspension was washed 3 times with complete medium, and the
concentration adjusted to 5.0 x 10 7 cells/ml.
Preparation of Bone Marrow Chimeras
Chimeras were prepared as described (2).

Female AKR/J

mice, 10 to 12 weeks old, were used as irradiated recipients
of marrow cells.

Mice were placed in a plastic chamber and

received a whole body dose of 10 Gy (dose rate= 2.0
Gy/minute) from a linear accelerator at Florida Hospital,
Orlando FL.

Approximately 2 to 4 hr following irradiation,

mice were infused via tail vein with 0.5 ml (2.5 x 10 7
cells) of the donor marrow suspension.

Chimeras were placed

in sterile micro-isolator cages and provided with sterile
food and water ad libitum.
Production of Murine IL-2
EL-4.IL-2 thymoma cells (American Type Culture
Collection, Rockville, MD) were cultured in complete medium.
EL-4.IL-2 cells were harvested from cultures and washed once
with complete medium.

Cells were resuspended to a

concentration of 2.0 x 10 6 cells/ml in RPMI 1640 medium with
5% serum.
flasks

Cells were cultured in Corning tissue culture

(Corning Glass Works, Corning, NY) for 48 hr in the

presence of an equal volume (40 ng/ml) of phorbol
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12-myristate 13-acetate (Sigma Chemical Co., St. Louis, MO)
(52).

At the end of the incubation period, culture

supernatants were harvested by centrifugation, sterilized by
filtration through a 0.22 micron filter membrane, and
assayed for biological activity.
contained 2 , 896 U/ml of IL-2.

The crude supernatant

The cell-free supernatant was

concentrated on an Amicon PM-10 membrane (Amicon
Corporation, Lexington, MA), and dialyzed against serum-free
medium.

The concentrated supernatant contained 16,000 U/ml

of IL-2.
Measurement of IL-2 Production by
Splenocytes
Interleukin-2 production of chimeras and B6 mice was
determined by culturing splenocytes (1.0 x 10 6 ) with 2 ug/ml
of Con-A for 24 hr.

After incubation, supernatants were

collected, filtered through a 0.22 micron membrane, and
assayed for IL-2 production using HT-2 cells.
Determination of IL-2 Activity
Measurement of IL-2 activity was performed using the
standard microassay (26).

HT-2 cells (American Type Culture

Collection, Rockville, MD.), an IL-2 dependent murine helper
T-cell line (21), were maintained in complete medium
supplemented with IL-2.

HT-2 cells were used as the target

cell population in the IL-2 microassay.

HT-2 cells were

washed twice in complete medium and resuspended to a
concentration of 5.0 x 10 4 cells/ml.

A volume of 0.1 ml

18

(5.0 x 10 3 ) of HT-2 cells was placed in wells of
microculture plates (Corning Glass Works, Corning, NY) to
which serial 2-fold dilutions of test supernatants
containing IL-2 had been prev~ously added.

Wells containing

HT-2 cells with a standard known quantity of IL-2, and wells
containing medium alone served as IL-2 and medium controls,
respectively.

Plates were incubated at 37°c in a humidified

atmosphere of 5%

co 2

in air for 24 hr.

Following

incubation, each microwell culture was pulsed for an
additional 4 hr with 1 uCi of tritiated thymidine ( 3 H-Tdr)
(New England Nuclear, Boston, MA).

Cultures were harvested

onto glass-fiber filter strips (Skatron Inc., Sterling, VA).
Filter strips were dried, placed in scintillation vials, and
4 ml of scintillation fluid (Fisher Scientific Co., Fair
Lawn, NJ) was added.

Thymidine incorgoration was used as an ·

index of culture proliferation and measured with a liquid
scintillation counter.
The IL-2 activity was quantified by probit analysis of
3 tt~Tdr incorporation data (26).

The transformation of data

for probit analysis was accomplished by assigning a value of
100% to the maximum counts per minute (cpm) of 3 H-Tdr
incorporated by HT-2 cells.

All other data points were

calculated as a percentage of the maximum.

The percentages

of maximum cpm were plotted against the reciprocal of sample
dilution and IL-2 ac.tivity was · expressed in units.
is defined as the reciprocal of the dilution of test

One unit
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supernatant that results in 50% of the maximum incorporation
3
of
H-Tdr by HT-2 cells.
Preparation of ·spleen and Thymus Cells
Spleen and thymus glands were aseptically removed and
gently teased into a suspension in complete medium.
Cellular debris was allowed to settle by placing cells on
ice for 5 minutes.
medium.

Cells were washed once with complete

· The number of viable lymphocytes was determined by

trypan blue exclusion using a hemacytometer.

Cells were

adjusted to the desired concentration in culture medium for
in vitro assays.
Response to In Vivo Immunization With SRBC
The ability of chimeras to respond to in vivo
sensitization with SRBC was evaluated.

Control B6 and

B6-AKR chimeras were injected intraperitoneally with 1 ml of
1% SRBC (Colorado Serum Co., Denver, CO).

Five days later,

spleens were aseptically removed and gently homogenized.
The viable cell concentration was adjusted to 1.0 x ·10 7
cells/ml.

One milliliter of each splenocyte suspension was

centrifuged, the supernatant removed, and 0.2 ml of complete
medium added to the cell pellet.

Plaque forming cell (PFC)

responses were analyzed using a modified form of the Jerne
plaque assay described by Cunningham (53).

A suspension of

the antibody-producing cells (0.05 ml) was mixed with
-

complement (0.05 ml) and target SRBC (0.05 ml) which had
been washed 3 times in complete medium.

A volume (0.05 ml)
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of the mixture was pipetted onto the glass at the inner edge
of the chamber which was then drawn into the chamber by
capillary action.
grease.

Chambers were sealed with stopcock

Slides were incubated at 37°c for 20 minutes.

The

number of plaques (clear zones of lysed SRBC surrounding a
central lymphocyte) was determined using light microscopy.
In Vivo Administration of IL-2
Murine IL-2 (16,000 U/mouse) was administered daily by
. intraperitoneal injection for 5 days.

The initial dose of

IL-2 (16,000 U) was mixed with a 1% washed SRBC (1 ml)
suspension.

On day 5 chimeras were sacrificed, and spleens

were aseptically removed.

Plaque forming cell responses of

splenocytes to in vivo immunization with SRBC were measured
(53).
Mitogenic Assays
In vitro proliferative responses to various mitogens
were evaluated using B6 and B6-AKR chimeric lymphoid cells
obtained from spleen and thymus.

Lymphoid cells were

cultured following the technique described by Alder et al.
(54).

Routinely, 2.0 x 10 5 lymphocytes were cultured in

complete medium in triplicate wells of microtiter test
plates.

Purified PHA (Sigma Chemical Co., St. Louis, MO) at

2.5, 5.0, 10.0, and 20.0, ug/ml and Con-A (Pharmacia,
Piscataway, NJ) at 1, 2, 4, and 8 ug/ml were added to
cultures.

All cultures were incubated at 37°C in a

humidified atmosphere of 5% co 2 in air for 96 hr.

During
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the last 24 hr, 1 uCi of 3 H-Tdr was added to cultures.
Cells were harvested onto glass-fiber filters.

Filter

strips were air dried and . placed in scintillation vials to
which 4 ml of scintillation fluid was added.

Cell

proliferation was determined by the amount of 3 H-Tdr
incorporated into DNA by liquid scintillation counting.
Results were expressed as cpm/culture (cpm with mitogen cpm with medium), with each value being the mean of three
determinations.
In Vitro Effect of RhIL-2 on
Splenocyte Mitogenic Responses
The effect of rhIL-2 on proliferative responses of
splenocytes to PHA and Con-A was analyzed.

Recombinant
-

human IL-2 was added at various concentrations 25, 50, and
100 U/well to splenocyte cultures that were stimulated with
various concentrations of Con-A (1, 2, 4, and 8 ug/ml) or
PHA (2.5, 5.0, 10.0, and 20.0 ug/ml) -for a 48 hr culture
period.

All cultures were established in triplicate for a

total of 96 hr at 37°c, with 5% co 2 in air.
24 hr, 1 uCi of 3 H-Tdr was added to cultures.

During the last
At the end of

the incubation period, cells were collected onto glass-fiber
filters.

Lymphocyte proliferative responses to PHA and

Con-A in the absence and presence of rhIL-2 were determined
by liquid scintillation counting.
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Kinetics of the In Vitro Effect of RhIL-2
on Mitogenic Responses
Kinetics of the rhIL-2 effect on splenocyte
proliferative responses to mitogens were estab lished.

In

the first series of experiments, rhIL-2 {SOU/well) was
added to mitogen stimulated cultures at various time points
following culture initiation.

Triplicate cultures were

incubated for a total of 96 hr at 31°c, and 5% co 2 in air.
A volume of 0.05 ml of 3 H-Tdr (1 uCi) was added to each well
for the last 24 hr of the incubation period.

Cells were

collected on glass-fiber filters and cpm were determined by
liquid scintillation counting.

In some experiments, rhIL-2

{SOU/well) was added to cultures at various time points (O,
24, and 48 hr) after culture initiation.

The duration of

exposure to rhIL-2 was 72 hr for all cultures.

Total PHA

incubation times were 72, 96, and 120 hr.
Assay for Activity of
7D4 Monoclonal Antibody
The hybridoma cell line (7 D4, CRL 1698, American Type
Culture Collection) which produces 7D4 antibody to the
murine IL-2 receptor was cultured in complete medium.
Supernatant fluids containing the antibody were collected
and filter sterilized through a 0.22 micron membrane filter.
The IL-2 dependent HT-2 cell line was used to analyze 7D4
activity.

HT-2 cells (5.0 x 10 3 ) were incubated in the

presence of various 2-fold dilutions of rhIL-2 (1/2, 1/4,
1/8, 1/16, 1/32, 1/64 and 1/28), and 0.05 ml of 7D4
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antibody.

After 24 hr, 1 uCi of 3 H-Tdr was added to each

culture.

Four hr later, proliferation was measured by the
3
incorporation of H-Tdr into DNA.
The percent inhibition of

proliferation was calculated from the following formula:
% inhibition= 1 _ cpm with antibody

X

100

cpm without antibody
Effect of 7D4 Antibody on
Proliferation of P815 Cells
P815 cells (55), were cultured with 0.05 ml of 7D4
antibody or complete medium for 24 hr. At the end of the
incubation time, 1 uCi of 3 H-Tdr was added to each culture.
Four hr later, proliferation was measured by the
incorporation of 3 H-Tdr into DNA.
Effect of 7D4 Antibody on
Thymocyte Proliferation
5
Thymocytes from B6 mice (2.0 x 10 cells/well). were
cultured in 96-well flat-bottomed microculture plates with
various concentrations of PHA (2.5, 5.0, 10.0, and 20.0
ug/ml), rhIL-2 (50 U), and 0.05 ml of supernatants
containing 7D4 antibody.
days.

Cultures were incubated for 3 or 4

One uCi of 3 H-Tdr was added to cultures for the last

24 hr of incubation.

Proliferation was measured by the

incorporation of 3 H-Tdr into: DNA.

The percent inhibition of

proliferation was measured as previously described.
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Effect of 7D4 Antibody on Mitogen-Induced
Proliferation of Splenocytes
Splenocytes (2.0 x 10 5 cells/well) were cultured in
96-well flat-bottomed microculture plates with various
concentrations of Con-A (i, 2, and 4 ug/ml) or PHA (2.5,
5.0, and 10.0 ug/ml) in the absence and presence of 0.05 ml
of supernatants containing 7D4 antibody for 3 or 4 days.
Cultures were pulsed for the last 24 hr with 3 H-Tdr.

After

incubation, cultures were harvested and the percent
inhibition of proliferation was determined.
Statistics
The statistical analysis used for the expression of the
data were as follows.
(SEM),

Mean+ standard error of the mean

and the student's t

distribution (P values).

RESULTS
The Effect of In Vivo Administration of
Murine IL-2 on the In Vivo SRBC Response and
IL-2 Production of B6-AKR Chimeric s lenoc tes
0 Days Post-transplant
Chimeras were injected intraperitoneally with murine
IL-2 for 5 days.

On day 5, IL-2 production and PFC antibody

response to SRBC were measured.

Chimeras treated with IL-2

demonstrated splenocyte PFC antibody response to SRBC
compared to non-IL-2 treated chimeras.

This response was

lower compared to that of normal B6 mice (Table I).
Interleukin-2 production in non-IL-2 treated chimeras was
not significantly different (P>0.1) from that of normal B6
mice (Table I).

Interleukin-2 treatment of chimeras

significantly suppressed IL-2 production (79%, P>0.01)
compared to non-IL-2 treated chimeras (Table I).
Effect of In Vivo Administration of RhIL-2
on IL-2 Production and Proliferative
Responses of Chimeric Splenocytes to Mitogeris
Chimeras were injected daily for 5 days with rhIL-2
(50,000 U).

Splenocytes from rhIL-2 treated chimeras and

control mice were cultured with various concentrations of
PHA or Con-A for 96 hr.

When the concentration of Con-A was

either 4 or 8 ug/ml, rhIL-2 treatment of chimeras enhanced
splenocyte proliferation.

However, at lower concentrations

(1 or 2 ug/ml of Con-A) no effect was observed (Table II).
Interleukin-2 production was not significantly different
25
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TABLE I
Effects Of In Vivo Administration Of Murine IL-2
On The In vivo SRBC Responses And IL-2 Production
Of Normal And Chimeric Splenocytes
(70 Days Post-transplant)

MICE

SPLEEN
WT
( g)

B6(2)b

SPLEEN
CELL 7
Xl0
IL-2a

0.12 +0.004

8.1+0.6

•B 6-AKR ( 3)

0.095+0.004

7.5+0.5

B6-AKR(5)

0.11 +0.007

7.2+0.7

PLAQUES
7llc+l3
<l

+

50+3

aIL-2 administered in vivo (80 000 U/mouse)
bNumber of animals
C

Average number of plaques+ SEM

IL-2
PRODUCTION
(U/ml)
77+22.9
46+10.8
16+1.3

TABLE II
Effects Of In Vivo Administration Of RhIL-2 On Con-A Mitogenesis
And IL-2 Production Of Chimeric Splenocytes
(120 Days Post-transplant)

3H-Tdr uptake (cpm)b
CON-A
MICE

IL-2a

lug/ml

2 ug/ml

4 ug/ml

8 ug/ml

IL-2
PRODUC'l'ION
(U/ml)

B6(3)c

74,821,:!:2,136

64,046,:!:16,979

36,567,:!:ll,753

8,321,:!:2,858

20. 7+1. 7

B6-AKR(2)

49,808,:!:10,194

45,999,:!:3,557

20,823,:!:828

4,534,:!:l,348

17.2+1.2

53,560,:!:4,228

43,723,:!:l,093

22,849,:!:411

7,756,:!:l,625

16. l+0. 9 .

B6-AKR(4)

+

aIL-2 administered in vivo (250 000 U/mouse)
bMean proliferative responses of animals tested+ SEM
cNumber of animals

N
...,J

28
(P>0.1) for rhIL-2 treated chimeras compared to non-IL-2
treated chimeras and normal B6 mice (Table II).

Recombinant

human IL-2 treatment of chimeras had no significant effect
(P>O.l) on PHA responsiveness of their splenocytes compared
to non-IL-2 treated chimeras (Table III).
In Vitro Effect of RhIL-2 on Con-A Mitogenesis
of Normal and Chimeric Splenocytes
(50 Days Post-transplant)
Splenocytes of chimeras and age-matched normal B6 mice
were cultured with various concentrations of Con-A for 96
hr.

Recombinant human IL-2 was added to splenocyte cultures

48 hr after culture initiation.

In the absence of rhIL-2,

splenocytes from B6 mice proliferated in response to 1, 2,
and 4 ug/ml of Con-A.
maximum at 1 ug/ml.

The proliferative response was
Recombinant human IL-2 at various

concentrations had no effect on Con-A mitogenesis of B6
splenocytes compared to cultures without rhIL-2 (Figure 1).
Splenocytes from chimeras proliferated in response to 1 and
2 ug/ml of Con-A.
ug/ml.

Maximum proliferation occurred at 1

Recombinant human IL-2 at various concentrations had

no effect on Con-A mitogenesis of chimeric splenocytes
compared to cultures without rhIL-2 (Figure 2).
In Vitro Effect of RhIL-2 on PHA Mitogenesis
of Normal and Chimeric Splenocytes
(50 Days Post-transplant)
Splenocytes of chimeras and age-matched normal B6 mice
were cultured with various concentrations of PHA for 96 hr.
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TABLE III
In Vivo Effect Of RhIL-2 On PHA
Responsiveness Of Chimeric Splenocytes
(120 Days Post-transplant)
3 H-Tdr Uptake (cpm)b
PHA
lOug/ml

20ug/ml

40ug/ml

7,329+529

4,061+305

3,157~530

2,685~543

-

2,075+518

2,188~754

1,562~405

1,511+61

B6-AKR(3) +

3,422+649

2,665~329

1,826+494

1,501+412

Mice

IL-2a

B6(3)c
B6-AKR(2)

5ug/ml

aIL-2 administered in vivo (250 000 U/mouse)
b

Mean proliferative responses of animals tested+ SEM

cNumber of animals

Figure 1.

In Vitro Effects of RhIL-2 on Con-A Mitogenesis
of B6 Splenocytes (50 Days Post-transplant).
Each point represents average values of 3 mice!
SEM.
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Figure 2.

In Vitro Effects of RhIL-2 on Con-A Mitogenesis
of Chimeric Splenocytes (50 Days Posttransplant).
Each point represents average values of 3 mice+
SEM.
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Recombinant human IL-2 was added to cultures 48 hr after
culture initiation.
Splenocytes from normal B6 mice proliferated in
response to various concentrations of PHA.

This

proliferative response demonstrated a Gaussian distribution
which was skewed to the right (Figure 3).
proliferation occurred at 10 ug/ml qf PHA.

Maximum
Recombinant

human IL-2 at various concentrations increased proliferative
responses to PHA at 2.5 and 5.0 ug/ml compared to cultures
without rhIL-2.

Increases in proliferative responses were

7.5 fold (P<0.05) and 4.0 fold (P<0.01), respectively
(Figure 3).

Splenocytes from chimeras demonstrated low

proliferative responses to PHA at various concentrations
tested (Figure 4).

Addition of rhIL-2 at various

concentrations significantly enhanced proliferative
responses to PHA compared to cultures without rhIL-2.
Increases in proliferative responses to PHA were 10.0 fold
(P<0.01),

6.0 fold (P<0.01), 4.8 fold (P<0.05), and 2.5 fold

(P<0.025) at 2.5,

s.o,

10.0, and 20.0 ug / ml, respectively.

Maximum proliferation occurred at 10 ug/ml of PHA in the
presence of various concentrations of rhIL-2 (Figure 4).

In Vitro Effect of RhIL-2 on Con-A Mitogenesis
of Normal and Chimeric Splenocytes
(70 Days Post-transplant)

Recombinant human IL-2 was added to Con-A stimulated
splenocytes 48 hr after culture initiation.
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Figure 4.

In Vitro Effects of RhIL-2 on PHA Mitogenesis
of Chimeric Splenocytes (50 Days Posttransplant).
Each point represents average values of 3 mice+
SEM.

20

=
=
=.

-a- NO IL-2
+ 25UIL-2
+ 50UIL-2
+ lOOUIL-2

1111"'4

~

"'

~

~

=
I

10

ff)

c...

0
~

~

u
0-1---.----....-----.----...---0
5 10
20
30
40
50

CONCENTRATION OF PHA (ug/ml)

Figure 5.

In Vitro Effects of RhIL-2 on Con-A Mitogenesis
of B6 Splenocytes (70 Days Post-transplant).
Each point represents average values of 3 mice!
SEM.
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Addition of rhIL-2 at various concentrations had no
effect on Con-A mitogenesis of either normal (Figure 5), or
chimeric splenocytes (Figure 6), compared to cultures
without rhIL-2.
In Vitro Effect of RhIL-2 on PHA Mitogenesis
of Normal and Chimeric Splenocytes
(70 Days Post-transplant)
Splenocytes from normal B6 mice proliferated in
response to various concentrations of PHA. Maximum
_proliferation occurred at 10 ug/ml of PHA.

Addition of

various concentrations of rhIL-2 increased proliferative
responses to PHA at 2.5 and 5.0 ug/ml compared to splenocyte
cultures without rhIL-2.

Increases in proliferative

responses were 3.1 fold (P<0.01) and 1.5 fold (P>0.01),
respectively (Figure 7).
Splenocytes from chimeras showed maximum proliferative
responses to PHA at 5 and 10 ug/ml (Figure 8).

Addition of

various concentrations of rhIL-2 significantly increased
proliferative responses to PHA at 2.5 and 5.0 ug/ml compared
to cultures without rhIL-2.

Increases were 2.0 fold

(P>0.05) and 1.7 fold (P>0.01), respectively.

In the

presence of rhIL-2 maximum proliferation occurred at 5 ug/rnl
of PHA (Figure 8).
In Vitro Effect of RhIL-2 on Con-A Mitogenesis
of Normal and Chimeric Splenocytes
(130 Days Post-transplant)
In the following experiment, SOU of rhIL-2 was added
to Con-A stimulated splenocytes 48 hr after culture

Figure 6.

In Vitro Effects of RhIL-2 on Con-A Mitogenesis
of Chimeric Splenocytes ( 70 Days Posttransplant).
Each point represents average values of 3 mice+
SEM.
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Figure 7.

In Vitro Effects of RhIL-2 on PHA Mitogenesis of
B6 Splenocytes (70 Days Post-transplant).
Each point represents average values of 3 mice+
SEM.
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Figure 8.

In Vitro Effects of RhIL-2 on PHA Mitogenesis of
Chimeric Splenocytes (70 Days Post-transplant).
Each point represents average values of 3 mice+
SEM.
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initiation.

In the absence of rhIL-2, splenocytes from B6

mice showed proliferative responses to Con-A at 1, 2, and 4
ug/ml (Figure 9).

Proliferative responses of B6 splenocytes

to Con-A (1 and 2 ug/ml) were enhanced after rhIL-2 addition
compared to cultures without rhIL-2.

However, the 1.5 fold

increase in proliferation was significant (P<0.025) only at
1 ug/m of Con-A {Figure 9).
The 1.3 fold increase in proliferative response of
chimeric splenocytes to Con-A (1 ug/ml) was significant
{P<0.05) after the addition of rhIL-2 compared to cultures
without rhIL-2 (Figure 10).
In Vitro Effect of RhIL-2 on PHA Mitogenesis
of Normal and Chimeric Splenocytes
(130 Days Post-transplant)
In the absence of rhIL-2, B6 splenocytes showed maximum
proliferative response to 10 ug/ml of PHA.

In the presence

of rhIL-2, significant enhancement of proliferation occurred
at 2.5 and 5.0 ug/ml compared to cultures without rhIL-2.
Increases in proliferative responses were 6.3 fold (P>0.05)
and 5.8 fold (P>0.01), respectively (Figure 11).

In the ·

presence of rhIL-2, maximum proliferation was shifted from
10 to 5 ug/ml (Figure 11).
In the absence of rhIL-2, chimeric splenocytes showed
m~ximum proliferation to 10 ug/ml of PHA.

In the presence

of rhIL-2, proliferation was enhanced to 2.5, 5.0, and 10.0
ug/ml of PHA compared to cultures witbout rhIL-2.

Increases

in proliferative responses were 2.5 fold (P<0.05), 6.0 fold
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(P>0.01), and 1.9 fold (P>0.01), respectively.

In the

presence of rhIL-2, maximum proliferation was shifted from
10 to 5 ug/ml (Figure 12).
Kinetics of the Enhancing Effect of RhIL-2
on Mitogenic Responses of B6 Splenocytes
Splenocytes from normal B6 mice were cultured with
Con-A or PHA for 96 hr.

Recombinant human IL-2 (50 U) was

added to splenocyte cultures at various time points after
culture initiation.

Recombinant human IL-2 significantly

increased splenocyte responsiveness (1.5 to 3.0 fold,
P<0.05) to Con-A at 1 and 2 ug/ml compared to cultures
without rhIL-2 (Figure 13).

These increases were similar

for each culture regardless of the time of rhIL-2 addition.
Recombinant human rhIL-2 significantly increased
splenocyte responsiveness (5.2 to 100 fold, P>0.005) to PHA
at 2.5, 5.0, and 10.0 ug/ml compared to cultures without
rhIL-2.

However, the degree of enhancement decreased when

rhIL-2 was added at 24 and 48 hr compared to 0, 0.5, and 1
hr cultures (Figure 14).
Effect of RhIL-2 Exposure Time
on PHA Mitogenesis of B6 Splenocytes
Recombinant human IL-2 (50 U) was added to PHA
stimulated cultures at 0, 24, and 48 hr after culture
in~tiation.

Incubation time with rhIL-2 was constant (72

hr) for all cultures.

Therefore, total incubation time for

PHA cultures were 72, 96, and 120 hr.

Figure 9.

In Vitro Effects of RhIL-2 on Con-A Mitogenesis
of B6 Splenocytes (l30 Days Post-transplant).
Each point represents average values of 3 mice+
SEM.
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Figure 11.

In Vitro Effects of RhIL-2 on PHA Mitogenesis
of B6 Splenocytes (130 Days Post-transplant).
Each point represents average values of 3 mice
+ SEM.
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Kinetics of the Enhancing Effects of RhIL-2 on
Con-A Mitogenesis of B6 Splenocytes.
Each bar represents average values of 3 mice
+ SEM.
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Kinetics of the Enhancing Effects of RhIL-2 on
PHA Mitogenesis of B6 Splenocytes.
Each bar represents average values of 3 mice
+ SEM.
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Proliferative response of splenocytes to PHA (5 ug/ml)
was enhanced when rhIL-2 was added at O, 24, and 48 hr
compared to cultures without rhIL-2.

The degree of

enhancement was similar for all cultures, regardless of the
total PHA incubation time (Figure 15).
Kinetics of RhIL-2 Enhancing Effect
on Mitogenic Responses of B6 Thymocytes
Thymocytes from normal mice were cultured with Con-A or
PHA for 96 hr.

Recombinant human IL-2 (50 U) was added to

splenocyte cultures at various time points after culture
initiation.

Recombinant human IL-2 (50 U) significantly

increased thymocytes responsiveness (P<0.05) to Con-A at 1
and 2 ug/ml compared to cultures without rhIL-2.

However,

the degree of- enhancement varied for each culture in
relation to the time of rhIL-2 addition and the
concentration of Con-A used.

No enhancement was observed in

cultures in which rhIL-2 was added at 48 hr (Figure 16).
Addition of rhIL-2 (50 U) to thymocytes at O, 0.5, and
1 hr after culture initiation increased proliferative
responses to PHA compared to . cultures without rhIL-2.

The

degree of enhancement was greater for cultures stimulated
with 10.0 ug/ml of PHA compared to those stimulated with 2.5
and 5.0 ug/ml.

The level of enhancement decreased in all

PHA cultures when rhIL-2 was added at 24 and 48 hr after
culture initiation (Figure 17).

Figure 15.

The Effect of IL-2 Exposure Time on PHA
Mitogenesis of B6 Splenocytes.
Each bar represents average values of 3 mice
+ SEM.
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Kinetics of the Enhancing Effects of RhIL-2 on
Con-A Mitogenesis of B6 Thymocytes.
Each bar represents average values of 3 mice
+ SEM.
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Kinetics of the Enhancing Effects of RhIL-2 o n
PHA Mitogenesis of B6 Thymocytes.
Each bar represents average values of 3 mice
+ SEM.
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Effect of 7D4 Antibody on Proliferation
of HT-2 Cells
HT-2 cells were cultured with various concentrations of
rhIL-2 in the absence or presence of 7D4 antibody (25% by
volume) for 24 hr.

The 7D4 antibody greatly inhibited the

proliferation of HT-2 cells (>80%) at all dilutions of
rhIL-2 tested (Figure 18).
Effect of 7D4 Antibody on
Proliferation of P815 Cells
P815 cells were incubated with various concentrations
of 704 antibody for 24 hr.

The 7D4 antibody did not inhibit

proliferation of P815 cells at any of the concentrations
tested (Table IV).
Analysis of the Effectiveness of 7D4
Antibody on Proliferation of Thymocytes to
PHA and RhIL-2
Thyrnocytes from B6 mice were cultured with various
concentrations of PHA and rhIL-2 (50 U) in the absence or
presence of 7D4 antibody (25% by volume) for 3 or 4 days •
.

The 7D4 antibody inhibited thymocyte proliferation to PHA
and rhIL-2 at all concentrations of PHA on both days 3 and
4.

This inhibition ranged from 77 to 98% (Table V).
Effect of 7D4 Antibody on
Con-A and PHA Mitogenesis of Splenocytes
Splenocytes from B6 mice were cultured with various

concentrations of PHA or Con-A in the absence or presence of
704 antibody.

The 7D4 antibody consistantly inhibited the

prol.iferation of spl.enocytes to Con- A or PHHA.

J[mJtniUt» "tt::iicom <mff

PHA mitogenesis ranged from 82 to 901 on day 3 aBIIOOli $$~ tt:aD
89% on day 4.

Inhibition of Con- A mritogemies.is :irann~ :fEltCm:m

76 to 98% on day 4 (Tabl.e VI).

Figure 18.

Effect of 704 Antibody on IL-2 Dependent
Proliferation of HT-2 Cells.
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TABLE IV
Effect Of 7D4 Antibody On Proliferation
Of P815 Cells

3H-Tdr uptake (cpm)
No 7D4

7D4 DILUTION
1/4

180,958±325

180,845±205

1/8
180,816±125

1/16
180,750±235

1/32
180,730±200

1/64
180,992±190

u,
u,

TABLE V
Effect Of 7D4 Antibody On The Proliferation
Of B6 Thymocytes To PUA And RhIL-2
3H-Tdr uptake (cpm)

3u-Tdr uptake (cpm)
EXPERIMENT
NO.

PUA+
IL-2a

DAY 3b
MEDIUM

7oi

' INHIBITION

MEDIUM

DAY 4

7D4

'

INHIBITION

1

10.oc
5.0
2.5

5,622
30,086
58,042

530
1,068
4,652.

91
96
92

2,,-02
27,282
113,747

296
466
2,768

89
98
98

2

10.0
5.0
2.5

8,256
43,396
87,398

520
1,306
4,682

93
97
95

3,190
28,218
105,680

222
414
1,074

93
99
99

3

10.0
5.0
2.5

3,950
33,636
56,204

910
1,450
5,062

77
96
91

4

10.0
5.0
2.5

4,694
28,112
72,134

630
1,270
6,194

87
95
91

-- d

a50 u
bTotal incubation time
cconcentration of PHA (ug/ml)
dNot tested

TABLE VI
Effect Of 7D4 Antibody On Mitogen-induced
Proliferation Of 86 Splenocytes
3H-Tdr uptake (cpm)

3H-Tdr uptake (cpm)

DAY 3a

MITOGEN
(ug/ml)

MEDIUM

7D4

10.0
5.0
2.5
CON-A 2.0
1.0

14,550
18,820
17,610

2,584
3,132
1,898

PHA 10.0
5.0
2.5
CON-A 2.0
1.0

16,100
36,646
41,508

EXPERIMENT
1

PHA

2

2,072
3,774
6,070

I INHIBITION

DAY 4
MEDIUM

82
83
89

7D4

I INHIBITION

--b
121,166
192,628

2,904
15,198

98
92

164,220
184,484

11,974
43,774

93
76

87
90
85

--

3

PHA 10.0
5.0
2.5
CON-A 4.0
2.0
1.0

4,272
15,458
7,843
75,112
132,942
164,758

1,796
2,782
2,204
2,476
13,154
10,120

58
82
72
97
90
94

4

PHA 10.0
5.0
2.5
CON-A 4.0
2.0
1.0

5,798
16,332
13,960
145,360
160,866
188,738

1,402
1,822
1,552
3,772
18,086
12,666

76
89
89
97
89
93

aTotal incubation time
bNot tested

u,
...J

DISCUSSION
IL-2 plays a major role in the regulation of immune
responses (26-28).
Utilizing both in vivo and in vitro assays, the
effectiveness of IL-2 in the enhancement of immune responses
in B6-AKR and normal B6 mice was investigated.
Chimeras [B6-AKR] are unable to generate anti-SRBC PFC
responses (2,3).

In this study, chimeras were analyzed for

their ability to generate PFC responses to SRBC after in

vivo treatment with murine IL-2.

In vivo treatment of

chimeras with murine IL-2 partially restored PFC responses
of their splenocytes to SRBC.

There are two possible

explanations for this limited restoration of PFC responses
in these chimeras.

The first possibility is that IL-2

directly affected B-cell differentiation to an antibody
producing state.

Therefore, the requirement for T-cell help

was bypassed for SRBC responsiveness.

It has been shown

that IL-2 can directly bind to B-cells and stimulate
antibody responsiveness (56).

The second possibility is

that IL-2 treatment expanded a minor subpopulation of helper
T-cells described previously in these chimeras (11,12).
These cells can interact with donor type cells in H2-I
incompatible chimeras.

Ultimately, these helper T-cells act

as essential elements in the PFC response to SRBC (11,12).
58
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The fact that these chimeras respond to a secondary
stimulation with SRBC (2,3), support the idea that these
minor subpopulations do exist, and are expanded by antigen
(SRBC)-induced IL-2.
Treatment of chimeras with murine IL-2 suppressed
splenocyte production of IL-2.

This suppressed IL-2

production was probably due to the presence of T-cell
specific suppressor factors in the crude preparations of
murine IL-2 used.

The presence of such suppressor factors

has been previously reported in supernatants of
alloantigen-activated splenocytes (57).
In order to determine the intrinsic role of IL-2 in
restoration of PFC responses in chimeras, it was essential
to use homogenously pure IL-2.

Treatment of chimeras with

the highly purified IL-2 (rhIL-2) failed to restore PFC
responses in these chimeras (data not shown).

However,

treatment of chimeras with rhIL-2 did not suppress IL-2
production of their splenocytes.

This finding further

supports the hypothesis that the suppression of IL-2
production in murine IL-2 treated chimeras is due to the
presence of suppressor factors in the crude preparations
used.

In vivo treatment of chimeras with rhIL-2 resulted in

a slight enhancement of mitogenic responses at higher, but
not lower concentrations of Con-A.

However, rhIL-2

treatment had no significant effect on mitogenic responses
of their splenocytes to various concentrations of PHA.

The
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fai1ure of rhIL-2 treatment to significant1y enhance
mitogenic responses to Con-A or PHA could be directly
related to the dose of -IL-2 used, and/or its short serum
half life

(58).

Therefore, the saturating levels of IL-2

could never be attained in these chimeras with the treatment
regimens used.
Since the use of rhIL-2 in vivo failed to significantly
enhance these immune functions, the effect of rhIL-2 on
sp l enocyte mitogenesis was studied in vitro.

The effect of

rhIL-2 in vitro was evaluated using three groups of normal
B6 and chimeric mice.

Several observations were made when

responses of these mice were compared.

Younger chimeras (50

days post-transplant) were suppressed in their responses to
PHA compared to the other age groups.

The low PHA response

in these chimeras was enhanced by rhIL-2 addition • . In
genera1, presence of rhIL-2 in PHA cultures enhanced
mitogenesis of splenocytes from B6 and chimeric mice
regardless of their age.
mitogen,

When Con-A was used as the

rhIL-2 enhanced proliferation of older (130 days

post-transplant), but not younger chimeras (50 and 70 days
post-transplant).

Fully a1logeneic B6-AKR chimeras are

unable to produce normal levels of IL-2 at later stages
post-transplant (> 100 days)

(3).

In the present study,

enhancement of mitogenic responses by rhIL-2 to PHA a nd
·
1:·-nd1·cate that despite their
Con-A in older chimeras,
.
th
re capable of respondi ng
deficiency in IL-2 production
ey a
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to IL-2 in mitogenic assays in vitro.

This enhanced

mitoge n ic response could be due to the ability of IL-2 to
u p regulate its own receptor expression (59,60).

These

findi ngs are similar to the results of studies using
perip heral blood from BMT patients ( 61 , 62).

In these

exper i me n ts, patients who were transplanted with bone marrow
were unab le to produce IL-2, but could respond to IL-2 when
added to lymphocyte cultures.
In this study, the inability of younger chimeras to
show enhanced Con-A mitogenesis to exogenous rhIL-2 in
v i tro, suggests that different mechanisms are involved in
the activation of splenocytes with PHA versus Con-A.

This

suggestion is directly related to differences in the level
of endogenous IL-2 in these two mitogenic assays.
Splenocytes stimulated with Con-A proguce high levels of
IL-2 (26).

However, PHA stimulated splenocytes produce very

low levels of IL-2 (46).

Therefore, one coul ~ speculate

that in younger chimeras which have normal levels of
en~ogenous IL-2, its receptors on Con-A activated
splenocytes were fully occupied with endogenous IL-2.

Thus,

the number of receptors available for exogenous IL-2 were
limiting for the enhancement of splenocyte proliferation to
Con-A.

These findings may indicate that PHA mitogenic

assays are more appropriate in the evaluation of enhancing
effects of exogenous IL-2 due to the absence of interfering
concentrations of endogenous IL-2.
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In order to determine the critical parameter for the
enhancement of mitogenic responses with rhIL-2, studies on
the kinetics of its enhancing effect were performed.

Since

the immunological state of fully allogeneic B6-AKR chimeras
has not been well characterized, studies were performed with
lymphoid cells from normal B6 mice (hemopoietic system of
B6-AKR chimeras).

When rhIL-2 was added to 96 hr splenocyte

cultures at various time points, Con-A responses were
greatly enhanced in all cultures, regardless of the total
exposure time to rhIL-2.

However, maximum enhancement of

PHA mitogenesis occurred when rhIL-2 was added at O and 1 hr
after culture initiation.

This degree of enhancement tended

to decrease when rhIL-2 was added at 24 or 48 hr.
experiments, there were two variables:

In these

the time of rhIL-2

addition, and the . total incubation period with rhIL-2.

In

order to determine which of these variables influenced the
level of enhancement, the incubation time with rhIL-2 was
kept constant for all cultures.

Similar levels of

enhancement were demonstrated for all cultures, regardless
of the time of rhIL-2 addition.

The length of incubation

time with exogenous IL-2 was the limiting factor in the
enhancement of PHA mitogenesis.

These findings, further

supported the speculation that different mechanisms are
involved in PHA stimulation of splenocytes compared to
Con-A.

Splenocytes stimulated with PHA bear lower numbers

of IL-2 receptors, and produce a limited amount of
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endogenous IL-2 compared to Con-A stimulated cultures (46).
These limitations in PHA stimulated cultures could result in
the requirement for longer incubation time with exogenous
rhIL-2.

Alternatively, enhanceraent of proliferation to PHA

could be due to IL-2 receptor upregulation by exogenous
rhIL-2.

Maximum enhancement would then require upregulation

of the number of receptors to optimal levels.

Upregulation

of a low number of IL-2 receptors would require a longer
.exposure time to rhIL-2.
In order to provide further evidence to support
speculations made for the kinetics of PHA stimulated
splenocytes, similar kinetic studies were performed on
thymocytes.

Thymocytes cultured with Con-A release 1% to 2%

of the level of IL-2 produced by Con-A stimulated
splenocytes (20).

A small percentage of activated

thymocytes express IL-2 receptors (46).

According to these

findings (20,46), thymocytes should demonstrate similar
kinetics to that shown by PHA stimulated splenocytes.

The

results indicated that thymocytes required a similar 72 to
96 hr exposure time to exogenous rhIL-2 for maximum
enhancement to occur.

Thus, PHA stimulated splenocytes and

thymocytes follow the same kinetic due to the limitation of
endogenous IL-2 and IL-2 receptors.
The 7D4 monoclonal antibody was used as a specific
inhibitor of IL-2 function in mitogenic assays.

The

proliferation ~f -splenocytes to different concentrations of
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PHA or Con-A was markedly inhibited by 7D4 antibody.
et al.

Malek

(46) had previously reported that the mixture of 7D4

and 3C7 failed to significantly inhibit the proliferation of
splenocytes to optimal concentrations of Con-A or PHA.

The

inhibition of splenocyte proliferation to Con-A or PHA by
7D4, in the present study, could be due to a non-specific
action of the 7D4 antibody.

However, the result of

experiments in which 7D4 antibody was tested on an unrelated
cell line, P815, ruled out this possibility.

Proliferation

of thymocytes to PHA and rhIL-2 was greatly inhibited by 7D4
antibody.

This finding was consistant with those previously

reported by Malek et al.

(46). Therefore, studies with 7D4

antibody provide direct evidence for the involvement of IL-2
in the proliferation of splenocytes to T-cell mitogens and
the proliferation of thyrnocytes in co-stimulatory assays.
In summary, critical parameters for examining the
mitogenic response of chimeras to T-cell mitogens and
exogenous IL-2 were identified.

Future studies will

evaluate IL-2 receptor expression on mitogen induced T-cell
blasts from chimeras and B6 mice.

These experiments will

determine if similar types of parameters are associated with
immunodeficiencies of long-term surviving, fully allogeneic
bone marrow chimeras.
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